Secondary prevention after acute myocardial infarction: Aspirin, warfarin or both?;Antitrombotisk profylakse etter hjerteinfarkt - Acetylsalisylsyre, warfarin eller begge?

Tidsskrift for den Norske Laegeforening

Volumn 123, Issue 13-14, 2003, Pages 1838-1840

  Reikvam, Åsmund ^a   Madsen, Steinar ^b   Landmark, Knud ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b Statens Legemiddelverk   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; AGED; AGING; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; HEART REINFARCTION; HUMAN; MORTALITY; SECONDARY PREVENTION; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HEART INFARCTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW;

ANTICOAGULANTS; ASPIRIN; CARDIOVASCULAR DISEASES; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; WARFARIN;

EID: 0142030099     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
2. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52.
3. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503.
4. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-74.
5. Eiring Ø. Åpner for Marevan-eksplosjon. Dagens Medisin 13.9.2001.
6. Breddin K, Loew D, Lechner K, Oberla K, Walter E. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980; 62: V63-72.
7. The E.P.S.I.M. Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982; 307: 701-8.
8. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350: 389-96.
9. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction primary results of the CHAMP study. Circulation 2002; 105: 557-63.
10. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360: 109-13.
11. Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 1998; 98: 1064-70.
12. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-62.
13. Cohen M, Adams PC, Parry G, Xiong PG, Chamberlain D, Wieczorek I et al. Combination antithrombotic therapy in unstable test angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation 1994; 89: 81-8.
14. Reikvam Å, Kvan E, Aursnes I. Use of cardiovascular drugs after acute myocardial infarction: a marked shift towards evidence-based drug therapy. Cardiovasc Drugs Ther 2002; 16: 451-6.
15. Arnesen H. Antitrombotisk behandling i ulike faser av koronar hjertesykdom. Plansje. Oslo: Nycomed, 1999.
16. Smith P, Arnesen H, Abdelnoor M. Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction. Arch Intern Med 1992; 152: 993-7.
17. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
18. Bertrand M, Simoons ML, Fox KA, Wallentin L, Hamm CW, McFadden E et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.